- Home
-
Technical Platform
-
Services
- TCR-T Lead Sequence Development Service
- Immune CAR Cell Preparation Technology Service
- Antibody Coupled Drug Discovery Service
- Antibody Affinity Maturation Service
- Antibody Humanization Services
- Bispecific Antibody Development Services
- Antibody Protein Sequencing Service
- Antibody Affinity Determination Service
Antibody Drugability Assessment
- Nucleic Acid Aptamer Synthesis Service
- Nucleic Acid Aptamer Modification Service
- Nucleic Acid Aptamer Library Construction Service
- Bispecific Aptamer Development Service
- Protein Nucleic Acid Aptamer Screening Service
- Metal Ion Nucleic Acid Aptamer Screening Service
- Small Molecule Nucleic Acid Aptamer Screening Service
- Cell Nucleic Acid Aptamer Screening Service
- Targeted Peptide Library Screening Service
- Targeted Peptide Library Construction Service
Active Peptide Discovery Technology Service
- mRNA Immune Antibody Preparation Service
- DNA Immune Antibody Preparation Service
Animal Immunization Technology Services
-
Technical Support
- Structural Basis for Selectivity and Antagonism in GPCR-Nanobodies
- Novel Peptide-Drug Conjugate (PDC) Shows Efficacy in Hepatocellular Carcinoma Models
- Nanobody Expression in Insect Cells
- Nanobody Mammalian Cell Expression
- Single-chain Antibody Library Construction Technology Introduction
- Prokaryotic Expression of Nanobodies
- Cell Line Immunogen of Nanobody
- Construction of Single Chain Antibody Library
- Nano-antibody/Single Domain Antibody Library Construction Service
- Customized Nano-antibody Immunogen3
- A PBD Dimer-Containing Antibody-Drug Conjugate (KK2845) Targeting TIM-3-Expressing AML
- A Novel Approach for Cancer Therapy - Modulating TCR Complex Recruitment to the T Cell Antigen Coupler (TAC) Enhances TAC-T Cell Function
- Development of Therapeutic Monoclonal Antibodies for Disease Treatment
- Common Problems and Solutions of Prokaryotic Expression of Recombinant Protein
- Neutralizing Monoclonal Antibody Development Service FAQ
- A Brief Discussion on Prokaryotic Expression of Recombinant Antibodies
- Common Problems and Solutions for Recombinant Antibody Yeast Expression Experiments
- Common Problems and Solutions for Recombinant Antibody Expression Experiments in lactation
- Recombinant Single-chain Antibodies Preparation Related Issues
- Common Problems and Solutions for Prokaryotic Expression Experiments of Recombinant Antibodies
Special topic on antibody modification
- Common Problems and Solutions for Yeast Two-hybrid Experiments
- Yeast Two-hybrid Technique Related Issues
- Common Problems and Solutions of Yeast Display Technology
- Overview of Yeast Two Hybrid System Principle and Application
- Introduction to Yeast Display Antibody Screening Technology
- Overview of Yeast Display Technology
- Overview of Yeast Two Hybrid Technology
- Yeast Display Platform for Rapid Nanobody Discovery
- What is the essential difference between antibody phage display and yeast display?
- Yeast One Hybrid FAQ
Yeast Display Technology Special Topic
- Antibody Affinity Testing(SPR)
- Hybridoma Gene Sequencing Process
- Antibody Affinity Detection (BLI)
- Antibody Affinity Test EC50
- Antibody Full Length Sequencing
Antibody Detection Service Topic
- How do you know Phage Display Peptide Library?
- Phage Display Peptide Library
- Phage Display Antibody Library Technology
- Efficient Screening Methods and Research Progress of Anti-tumor Polypeptides
- Molecular Screening and Application of Targeted Peptides
- Screening Strategies for Cyclic Peptide Drugs
- Construction Method of Random Peptide Library
- Construction and Screening of Peptide Library
- Overview of Phage Displayed Peptide Library Technology
- Overview of Peptide Library Screening Methods
Special Topic on Phage Display Technology
- Application And Prospects of CAR-T Technology in Tumor Immunotherapy
- CAR-T Discovery Service
CAR-T Molecule Discovery Topic
- The Promise of Small Nucleic Acid Therapeutics: From Bench to Clinic as Next-Generation Medicines
- Issues Related to Aptamer Library Screening
- Introduction to Nucleic Acid Aptamer Library Screening Technology
- Overview of Aptamer Synthesis Technology
- Screening and optimization of nucleic acid aptamers
- Screening and Application of Peptide Aptamers
- Main Research Directions Progress and Challenges of Nucleic Acid Aptamer Screening Technology
- Research Progress of Protein Nucleic Acid Aptamer Screening
- Research Progress of Aptamer Screening-of Small Molecule Targets
- Nucleic Acid Aptamer Libraries Screening: an Efficient Method for Discovering Specific Binding Molecules
Molecular Biology Service Topics
-
Product Center
- Contact Us
Product Center
About US
-
Phone
400-168-8285 -
Email
info@tekbiotech.com -
Address
Building A5, International Enterprise Community, Wuqing, Tianjin
Inquiry and ordering
Product Center
TekBiotech understands your critical needs in drug discovery and quality control. Your work demands rigorous consistency between batches, superior biological activity, and ultra-low endotoxin levels—and we are built to deliver. We have developed a compreh
Recombinant AntibodyAnti-IGHE重组抗体|科研级 Quilizumab ( 奎利珠单抗 )
Datasheet
- TKYR1270
- 科研级 Quilizumab ( 奎利珠单抗 ), Anti-IGHE Recombinant Antibody, Research Grade Quilizumab
- Quilizumab
- 1mg, 5mg
- 1228538-47-3
Anti-ERBB3重组抗体|科研级 Patritumab ( 帕曲妥单抗 )
Datasheet
- TKYR1271
- 科研级 Patritumab ( 帕曲妥单抗 ), Anti-ERBB3 Recombinant Antibody, Research Grade Patritumab
- Patritumab
- 1mg, 5mg
- 1262787-83-6
Anti-Toxin A重组抗体|科研级 Actoxumab ( 阿克托舒单抗 )
Datasheet
- TKYR1272
- 科研级 Actoxumab ( 阿克托舒单抗 ), Anti-Toxin A Recombinant Antibody, Research Grade Actoxumab
- Actoxumab
- 1mg, 5mg
- 1245634-25-6
Anti-Toxin B重组抗体|科研级 Bezlotoxumab ( 贝洛托舒单抗 )
Datasheet
- TKYR1273
- 科研级 Bezlotoxumab ( 贝洛托舒单抗 ), Anti-Toxin B Recombinant Antibody, Research Grade Bezlotoxumab
- Bezlotoxumab
- 1mg, 5mg
- 1246264-45-8
Anti-PCSK9重组抗体|科研级 Alirocumab ( 阿利苏单抗 )
Datasheet
- TKYR1274
- 科研级 Alirocumab ( 阿利苏单抗 ), Anti-PCSK9 Recombinant Antibody, Research Grade Alirocumab
- Alirocumab
- 1mg, 5mg
- 1245916-14-6
Anti-IL6重组抗体|科研级 Clazakizumab ( 克拉扎珠单抗 )
Datasheet
- TKYR1275
- 科研级 Clazakizumab ( 克拉扎珠单抗 ), Anti-IL6 Recombinant Antibody, Research Grade Clazakizumab
- Clazakizumab
- 1mg, 5mg
- 1236278-28-6
Anti-DLL4重组抗体|科研级 Demcizumab ( 登赛珠单抗 )
Datasheet
- TKYR1276
- 科研级 Demcizumab ( 登赛珠单抗 ), Anti-DLL4 Recombinant Antibody, Research Grade Demcizumab
- Demcizumab
- 1mg, 5mg
- 1243262-17-0
Anti-ERBB3重组抗体|科研级 Duligotuzumab ( 度戈妥珠单抗 )
Datasheet
- TKYR1277
- 科研级 Duligotuzumab ( 度戈妥珠单抗 ), Anti-ERBB3 Recombinant Antibody, Research Grade Duligotuzumab
- Duligotuzumab
- 1mg, 5mg
- 1314238-96-4
Anti-DLL4重组抗体|科研级 Enoticumab ( 依诺苏单抗 )
Datasheet
- TKYR1278
- 科研级 Enoticumab ( 依诺苏单抗 ), Anti-DLL4 Recombinant Antibody, Research Grade Enoticumab
- Enoticumab
- 1mg, 5mg
- 1192578-27-0
Anti-NGF重组抗体|科研级 Fasinumab ( 法司努单抗 )
Datasheet
- TKYR1279
- 科研级 Fasinumab ( 法司努单抗 ), Anti-NGF Recombinant Antibody, Research Grade Fasinumab
- Fasinumab
- 1mg, 5mg
- 1190239-42-9
To experience the reliable service of Tekbiotech please subscribe:
-
Antibody Discovery
-
Antibody Production
-
Antibody Modification
Contact
- Phone：400-168-8285
- Email：info@tekbiotech.com
- Address：Building A5, International Enterprise Community, Wuqing, Tianjin
Follow us!
Technical Support
©2026Tekbiotech (Tianjin) Co., Ltd